At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SNDX Syndax Pharmaceuticals
Pre-Mkt 07-22 05:46:04 EDT
22.64
+0.35
+1.57%
High22.72Low22.10Vol1.19M
Open22.37D1 Closing22.29Amplitude2.78%
Mkt Cap2.00BTradable Cap1.80BTotal Shares88.20M
T/O26.64MT/O Rate1.49%Tradable Shares79.61M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
TIPRANKS  ·  07-20 15:57
Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst
TradingKey Daily Market Briefing: Oil Prices Rise Above $90, AI Semiconductors Continue to Face Pressure, Nvidia, TSMC, AMD Fall Collectively
TradingKey  ·  07-20 08:51
TradingKey Daily Market Briefing: Oil Prices Rise Above $90, AI Semiconductors Continue to Face Pressure, Nvidia, TSMC, AMD Fall Collectively
AI Chip Sell-Off Enters Third Straight Session: Why Are NVDA, AMD, Intel, Micron, and SNDK Falling Today, 7/17/26?
TIPRANKS  ·  07-17
AI Chip Sell-Off Enters Third Straight Session: Why Are NVDA, AMD, Intel, Micron, and SNDK Falling Today, 7/17/26?
Tech and Chip Stocks Plunge as Wall Street Volatility Resurfaces
Deep News  ·  07-17
Tech and Chip Stocks Plunge as Wall Street Volatility Resurfaces
Top 20 US Stocks by Trading Volume on July 17: Google Delays Launch of Gemini Flagship Model
Deep News  ·  07-17
Top 20 US Stocks by Trading Volume on July 17: Google Delays Launch of Gemini Flagship Model
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story
Simply Wall St.  ·  07-16
Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)
TIPRANKS  ·  07-15
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)
Syndax Pharmaceuticals Price Target Maintained with a $40.00/share by HC Wainwright & Co.
Dow Jones  ·  07-15
Syndax Pharmaceuticals Price Target Maintained with a $40.00/share by HC Wainwright & Co.
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX)
TIPRANKS  ·  07-15
Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX)
Syndax Posts R&D Day Presentation on Revumenib and Axatilimab Pipeline Expansion
Reuters  ·  07-14
Syndax Posts R&D Day Presentation on Revumenib and Axatilimab Pipeline Expansion
Syndax Unveils Mutant-selective EGFR Inhibitor Sndx-4321, Targets IND Filing by End-2026
Reuters  ·  07-14
Syndax Unveils Mutant-selective EGFR Inhibitor Sndx-4321, Targets IND Filing by End-2026
Semiconductor Stocks Drag Down US Index Futures; SK hynix Slides 10% in Premarket
Deep News  ·  07-13
Semiconductor Stocks Drag Down US Index Futures; SK hynix Slides 10% in Premarket
Micron, Delta, Strategy, Circle Internet, and More Stocks That Explain Today's Market
Dow Jones  ·  07-10
Micron, Delta, Strategy, Circle Internet, and More Stocks That Explain Today's Market
Syndax CEO Michael Metzger Disposes of Common Shares Worth $784,274.98
Reuters  ·  07-10
Syndax CEO Michael Metzger Disposes of Common Shares Worth $784,274.98
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next
Simply Wall St.  ·  07-08
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Reuters  ·  07-07
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Etoro Data Show Retail Investors Pile into Memory Stocks as AI Data Center Demand Strains Supply
Reuters  ·  07-06
Etoro Data Show Retail Investors Pile into Memory Stocks as AI Data Center Demand Strains Supply
Pre-Market Surge for U.S. Memory Chip Stocks as Semiconductor Sector Receives Major Update
Deep News  ·  07-06
Pre-Market Surge for U.S. Memory Chip Stocks as Semiconductor Sector Receives Major Update
Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?
Simply Wall St.  ·  07-05
Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?
Top 20 US Stocks by Trading Volume on July 3: Tesla Caps Employee AI Spending at $200 Weekly
Deep News  ·  07-03
Top 20 US Stocks by Trading Volume on July 3: Tesla Caps Employee AI Spending at $200 Weekly

Introduction

Company Name.
Syndax Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Issue price:
--